Elizabeth H Byrne1, Melis N Anahtar1, Kathleen E Cohen1, Amber Moodley2, Nikita Padavattan3, Nasreen Ismail3, Brittany A Bowman1, Gregory S Olson1, Amanda Mabhula4, Alasdair Leslie4, Thumbi Ndung'u5, Bruce D Walker6, Musie S Ghebremichael1, Krista L Dong2, Douglas S Kwon7. 1. Ragon Institute of MGH, MIT and Harvard, Massachusetts General Hospital, Cambridge, MA, USA. 2. Females Rising through Education, Support, and Health, Durban, KwaZulu-Natal, South Africa. 3. HIV Pathogenesis Programme, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa. 4. KwaZulu-Natal Research Institute for Tuberculosis and HIV, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa. 5. Ragon Institute of MGH, MIT and Harvard, Massachusetts General Hospital, Cambridge, MA, USA; HIV Pathogenesis Programme, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa; KwaZulu-Natal Research Institute for Tuberculosis and HIV, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa; Max Planck Institute for Infection Biology, Chariteplatz, Berlin, Germany. 6. Ragon Institute of MGH, MIT and Harvard, Massachusetts General Hospital, Cambridge, MA, USA; Division of Infectious Diseases, Massachusetts General Hospital, Cambridge, MA, USA; Howard Hughes Medical Institute, Chevy Chase, MD, USA. 7. Ragon Institute of MGH, MIT and Harvard, Massachusetts General Hospital, Cambridge, MA, USA; Division of Infectious Diseases, Massachusetts General Hospital, Cambridge, MA, USA. Electronic address: dkwon@mgh.harvard.edu.
Abstract
BACKGROUND: The use of injectable progestin-only contraceptives has been associated with increased risk of HIV acquisition in observational studies, but the biological mechanisms of this risk remain poorly understood. We aimed to assess the effects of progestins on HIV acquisition risk and the immune environment in the female genital tract. METHODS: In this prospective cohort, we enrolled HIV-negative South African women aged 18-23 years who were not pregnant and were living in Umlazi, South Africa from the Females Rising through Education, Support, and Health (FRESH) study. We tested for HIV-1 twice per week to monitor incident infection. Every 3 months, we collected demographic and behavioural data in addition to blood and cervical samples. The study objective was to characterise host immune determinants of HIV acquisition risk, including those associated with injectable progestin-only contraceptive use. Hazard ratios (HRs) were estimated using Cox proportional hazards methods. FINDINGS: Between Nov 19, 2012, and May 31, 2015, we characterised 432 HIV-uninfected South African women from the FRESH study. In this cohort, 152 women used injectable progestin-only contraceptives, 43 used other forms of contraception, and 222 women used no method of long-term contraception. Women using injectable progestin-only contraceptives were at substantially higher risk of acquiring HIV (12·06 per 100 person-years, 95% CI 6·41-20·63) than women using no long-term contraception (3·71 per 100 person-years, 1·36-8·07; adjusted hazard ratio [aHR] 2·93, 95% CI 1·09-7·868, p=0·0326). HIV-negative injectable progestin-only contraceptive users had 3·92 times the frequency of cervical HIV target cells (CCR5+ CD4 T cells) compared with women using no long-term contraceptive (p=0·0241). Women using no long-term contraceptive in the luteal phase of the menstrual cycle also had a 3·25 times higher frequency of cervical target cells compared with those in the follicular phase (p=0·0488), suggesting that a naturally high progestin state had similar immunological effects to injectable progestin-only contraceptives. INTERPRETATION: Injectable progestin-only contraceptive use and high endogenous progesterone are both associated with increased frequency of activated HIV targets cells at the cervix, the site of initial HIV entry in most women, providing a possible biological mechanism underlying increased HIV acquisition in women with high progestin exposure. FUNDING: The Bill and Melinda Gates Foundation and the National Institute of Allergy and Infectious Diseases.
BACKGROUND: The use of injectable progestin-only contraceptives has been associated with increased risk of HIV acquisition in observational studies, but the biological mechanisms of this risk remain poorly understood. We aimed to assess the effects of progestins on HIV acquisition risk and the immune environment in the female genital tract. METHODS: In this prospective cohort, we enrolled HIV-negative South African women aged 18-23 years who were not pregnant and were living in Umlazi, South Africa from the Females Rising through Education, Support, and Health (FRESH) study. We tested for HIV-1 twice per week to monitor incident infection. Every 3 months, we collected demographic and behavioural data in addition to blood and cervical samples. The study objective was to characterise host immune determinants of HIV acquisition risk, including those associated with injectable progestin-only contraceptive use. Hazard ratios (HRs) were estimated using Cox proportional hazards methods. FINDINGS: Between Nov 19, 2012, and May 31, 2015, we characterised 432 HIV-uninfected South African women from the FRESH study. In this cohort, 152 women used injectable progestin-only contraceptives, 43 used other forms of contraception, and 222 women used no method of long-term contraception. Women using injectable progestin-only contraceptives were at substantially higher risk of acquiring HIV (12·06 per 100 person-years, 95% CI 6·41-20·63) than women using no long-term contraception (3·71 per 100 person-years, 1·36-8·07; adjusted hazard ratio [aHR] 2·93, 95% CI 1·09-7·868, p=0·0326). HIV-negative injectable progestin-only contraceptive users had 3·92 times the frequency of cervical HIV target cells (CCR5+ CD4 T cells) compared with women using no long-term contraceptive (p=0·0241). Women using no long-term contraceptive in the luteal phase of the menstrual cycle also had a 3·25 times higher frequency of cervical target cells compared with those in the follicular phase (p=0·0488), suggesting that a naturally high progestin state had similar immunological effects to injectable progestin-only contraceptives. INTERPRETATION: Injectable progestin-only contraceptive use and high endogenous progesterone are both associated with increased frequency of activated HIV targets cells at the cervix, the site of initial HIV entry in most women, providing a possible biological mechanism underlying increased HIV acquisition in women with high progestin exposure. FUNDING: The Bill and Melinda Gates Foundation and the National Institute of Allergy and Infectious Diseases.
Authors: Amie L Meditz; Michelle K Haas; Joy M Folkvord; Kelsey Melander; Russ Young; Martin McCarter; Samantha Mawhinney; Thomas B Campbell; Yolanda Lie; Eoin Coakley; David N Levy; Elizabeth Connick Journal: J Virol Date: 2011-08-03 Impact factor: 5.103
Authors: Melis N Anahtar; Elizabeth H Byrne; Kathleen E Doherty; Brittany A Bowman; Hidemi S Yamamoto; Magali Soumillon; Nikita Padavattan; Nasreen Ismail; Amber Moodley; Mary E Sabatini; Musie S Ghebremichael; Chad Nusbaum; Curtis Huttenhower; Herbert W Virgin; Thumbi Ndung'u; Krista L Dong; Bruce D Walker; Raina N Fichorova; Douglas S Kwon Journal: Immunity Date: 2015-05-19 Impact factor: 31.745
Authors: Catriona S Bradshaw; Jennifer Walker; Christopher K Fairley; Marcus Y Chen; Sepehr N Tabrizi; Basil Donovan; John M Kaldor; Kathryn McNamee; Eve Urban; Sandra Walker; Marian Currie; Hudson Birden; Francis Bowden; Suzanne Garland; Marie Pirotta; Lyle Gurrin; Jane S Hocking Journal: PLoS One Date: 2013-03-05 Impact factor: 3.240
Authors: Christina Gosmann; Melis N Anahtar; Scott A Handley; Mara Farcasanu; Galeb Abu-Ali; Brittany A Bowman; Nikita Padavattan; Chandni Desai; Lindsay Droit; Amber Moodley; Mary Dong; Yuezhou Chen; Nasreen Ismail; Thumbi Ndung'u; Musie S Ghebremichael; Duane R Wesemann; Caroline Mitchell; Krista L Dong; Curtis Huttenhower; Bruce D Walker; Herbert W Virgin; Douglas S Kwon Journal: Immunity Date: 2017-01-10 Impact factor: 31.745
Authors: Albert Garcia-Minambres; Sahar G Eid; Niamh E Mangan; Corinna Pade; San S Lim; Antony Y Matthews; Nicole A de Weerd; Paul J Hertzog; Johnson Mak Journal: Immunol Cell Biol Date: 2017-01-03 Impact factor: 5.126
Authors: Jennifer A Juno; Kathleen M Wragg; Anne B Kristensen; Wen Shi Lee; Kevin J Selva; Renee M van der Sluis; Anthony D Kelleher; Benjamin R Bavinton; Andrew E Grulich; Sharon R Lewin; Stephen J Kent; Matthew S Parsons Journal: J Virol Date: 2019-05-15 Impact factor: 5.103
Authors: Abigail Liberty; Kimberly Yee; Blair G Darney; Ana Lopez-Defede; Maria I Rodriguez Journal: Am J Obstet Gynecol Date: 2019-12-14 Impact factor: 8.661
Authors: Athena P Kourtis; Lisa Haddad; Jennifer Tang; Lameck Chinula; Stacey Hurst; Jeffrey Wiener; Sascha Ellington; Julie A E Nelson; Amanda Corbett; Kristina De Paris; Caroline C King; Mina Hosseinipour; Irving F Hoffman; Denise J Jamieson Journal: Contemp Clin Trials Date: 2016-11-09 Impact factor: 2.226